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Purpose: 
  The purpose of this study is to investigate whether the combination of anti-PD-1 
antibody (aPD1-ab), a checkpoint inhibitor, and bone marrow-derived dendritic cells 
(BM-DCs) following X-ray radiotherapy improves local tumor control and whether this 
combination therapy enhances systemic antitumor immunity and promotes abscopal 
effects in a murine B16/BL6 model. 
Materials and methods: 
  B16/BL6 cells were irradiated with 0, 2, 4, 8, 12, or 16 Gy X-rays and incubated 
further. After 72 h of incubation, the cells were collected and analyzed using flow 
cytometer.  
  For mouse model, B16/BL6 cells were implanted subcutaneously in the left thigh of 
syngeneic C57BL/6 mice [B6(Cg)Tyrc-2J/J] as primary tumors. BM-DCs were 
induced from bone marrow cells using GM-CSF and IL-4. The primary tumors were 
treated with 8 Gy X-ray, followed by simultaneous intratumoral injection of BM-DCs 
and intraperitoneal injection of aPD1-ab. To examine the abscopal effect, B16/BL6 
cells were also inoculated in the right thighs as metastatic tumors 4 or 26 days after the 
left side primary tumor inoculation, and only the primary tumors were treated with the 
same protocols. In vivo analyses of tumor growth and survival rates as well as in vitro 
analyses of splenic T-cell proliferation and interferon-γ (INF-γ) release were performed. 
Results: 
  The PD-L1 expression decreased with increase in irradiation dose, especially in 
dying cells. The expression of H-2kd was low before irradiation, it increased 
significantly after X-ray irradiation in a dose-dependent manner, especially in dying 
cells. 
  The induced BM-DCs were approximately 80% of the collected cells. The harvested 
BM-DCs were positive for all markers (CD40, CD80, CD86, I-A/I-E) and the induced 
BM-DCs have a good function to endocytose antigens. 
  In the mouse model, the triple combination treatment of X-ray irradiation with BM-
DCs and aPD1-ab administration inhibited primary tumor growth and significantly 
extended the survival time. In addition, this triple combination treatment significantly 
inhibited the growth of metastatic tumors. 
Discussion: 
  In this study, we aimed to improve the local control and prevent or cure distant 
metastases of cancers using tumor-specific immune response. Although radiotherapy 
of tumors may act as “in situ vaccine”, this effect depends on the balance between 
promotion and inhibition of immune response in the tumor microenvironment and also 
depends on radiation dose, dose rate, and the number of surviving immune cells. 
  We induced DCs from syngeneic bone marrow cells and the harvested cells contain 
approximately 15% macrophages. The contaminated macrophages may suppress the 
anti-tumor immune response and promote tumor cell metastasis. Also, it is difficult to 
predict the number of injected immature DCs that will transform into regulatory DCs 
that suppress the immune response which needs to be solved in the future study. 
  In addition, certain risks are associated with intratumoral injection of DCs. 
Intratumoral injection may be technically difficult and risky for deep-seated tumors. 
Other possible risks associated with DC and aPD1-ab treatment may include induction 
of a cytokine storm and induction of autoimmune disorders because of checkpoint 
inhibition. 
  Vanpouille-Box et al. reported that TGF-β was a major negative regulator of in situ 
tumor vaccination induced by irradiation. Although the triple combination of RT, DC, 
and aPD1-ab acted synergistically in this study, the optimal combinations with local 
radiation should be determined from a view point of safety, efficacy, and feasibility for 
clinical translation. 
Conclusions: 
  The combination treatment of intratumoral BM-DC injection and intraperitoneal 
administration of aPD1-ab after localized X-ray irradiation significantly inhibited local 
tumor growth and extended the survival time of mice bearing subcutaneous tumors. In 
addition, this combination treatment can convert the tumors to in situ vaccines, inducing 
an effective systemic antitumor immunoreaction that may be used for treating or 
preventing metastatic tumors. 
